Romosozumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Romosozumab and local guidelines before prescribing.
Anabolic bone agent
Mechanism
Sclerostin monoclonal antibody (anabolic).
Uses
Severe osteoporosis at high fracture risk.
Dosing
- Romosozumab | 210 mg SC monthly for 12 months (NICE TA791). Contraindicated after MI or stroke. Follow with an antiresorptive.
Endocrinology: Bone Medicine
Side effects
Hypocalcaemia, arthralgia, injection-site reaction; MI and stroke risk.
Interactions
Few.
Contraindications and cautions
Prior MI or stroke, hypocalcaemia
Monitoring
Calcium, cardiovascular risk
Pregnancy and breastfeeding
Not for use
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Contraindicated after MI or stroke in the last year; follow with antiresorptive therapy.
More from the textbook: uses, cautions and other points
- Romosozumab (anti-sclerostin, monthly for 12 months) - avoid with a history of MI or stroke .
Endocrine: Anatomy Physiology and Pharmacology - Teriparatide / romosozumab | Bone-building; romosozumab - avoid after MI or stroke.
Endocrine: Anatomy Physiology and Pharmacology - Romosozumab (monthly SC for 12 months) | Anti- sclerostin — increases formation and reduces resorption | Very high fracture risk in postmenopausal women; contraindicated after MI or stroke (CV signal)
Rheumatology Anatomy Physiology Pharmacology - Anabolic: Stimulate osteoblasts to build new bone - teriparatide, abaloparatide, romosozumab. These produce bigger, faster gains.
Endocrinology: Bone Medicine - Anabolic courses: Fixed duration (teriparatide 24 months, abaloparatide 18 months, romosozumab 12 months), always followed by antiresorptive treatment.
Endocrinology: Bone Medicine - Very high risk: anabolic first (teriparatide, abaloparatide, romosozumab), always followed by an antiresorptive.
Endocrinology: Bone Medicine - NICE TA791: Romosozumab for severe osteoporosis
Endocrinology: Bone Medicine - Osteocytes — embedded osteoblasts — sense mechanical load; produce sclerostin (inhibits bone formation — target of romosozumab) and FGF23 (phosphate control).
Rheumatology Anatomy Physiology Pharmacology
Where it is discussed in the book
- Endocrine: Anatomy Physiology and Pharmacology (2 mentions)
- Endocrinology: Bone Medicine (5 mentions)
- Rheumatology Anatomy Physiology Pharmacology (4 mentions)
- Medicine of the older adult.: Falls, syncope, mobility and fragility fractures (2 mentions)
- 0230 (1 mention)